

AUROBAC TX AT A GLANCE



- ✓ **Founded in 2022** by Boehringer Ingelheim, bioMérieux and Evotec
- ✓ **30 FTEs** as of March 2026



Experienced Board & Management team with a **proven track record** of building successful drug development companies and bringing anti-infective drugs to approval



Building a differentiated pipeline of innovative, first-in-class drugs to **fight antimicrobial resistance, bacterial infections, and their consequences in acute hospital settings**



Covering the entire value chain of R&D from discovery to market

PARTNERING OBJECTIVES FOR BIO US

AUROBAC is interested in **co-developing, in-licensing or acquiring** drug candidates that meet the following criteria:

- **Antimicrobials targeting Gram-negative ESKAPE pathogens** such as *P. aeruginosa*, *K. pneumoniae* and/or *A. baumannii*, and/or **host-targeted approaches**
- **Developed for the treatment of acute respiratory infections** (HABP, VABP) and/or **sepsis/septic shock**
- From **Lead Optimization to Phase 1**